Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025	Mar. 31, 2025
Current assets:
Cash and cash equivalents	$ 38,791	$ 33,180
Short-term investments	163,981	202,522
Prepaid expenses and other current assets	6,493	5,914
Total current assets	209,265	241,616
Property and equipment, net	130	100
In-process R&D	11,364	11,636
Other non-current assets	886	84
Total assets	221,645	253,436
Current liabilities:
Accounts payable	4,496	5,757
Accrued expenses and other current liabilities	11,043	14,639
Total current liabilities	15,539	20,396
Long-term liabilities:
Long-term debt	30,067	29,907
Total liabilities	45,606	50,303
Commitments and Contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.001 par value, 300,000,000 authorized as of March 31, 2026 and December 31, 2025; 204,922,140 and 204,567,283 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	204	204
Additional paid-in capital	821,635	811,103
Accumulated other comprehensive loss	(429)	(87)
Accumulated deficit	(645,371)	(608,087)
Total stockholders’ equity	176,039	203,133	$ 147,850
Total liabilities and stockholders’ equity	$ 221,645	$ 253,436

In-process research and development.

No definition available.

Name:	svra_InProcessResearchAndDevelopment
Namespace Prefix:	svra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).